Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2 study of MultiStem cell therapy for early treatment and prevention of complications after severe traumatic injury

Next Previous
Trial Profile

A phase 2 study of MultiStem cell therapy for early treatment and prevention of complications after severe traumatic injury

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Invimestrocel (Primary)
  • Indications Traumatic brain injuries
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms MATRICS-1

Most Recent Events

  • 01 Jun 2023 According to an Athersys media release, this trial is supported in part by MTEC (Medical Technology Enterprise Consortium) in partnership with the Department of Defense, and funding from Memorial Hermann Foundation.
  • 01 Jun 2023 According to an Athersys media release, patient enrollment has begun in the third and final cohort in this trial, and approximately 140 patients will be enrolled in cohort three.
  • 18 May 2023 According to Athersys media release, Completed DSMB review of cohort 1 & 2 of MATRICS trauma trial using both cell factory and bioreactor manufactured clinical product.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top